Tegonat 5.8mg/15.8mg/20mg Capsule: Product and Procurement Guide
Looking for Tegonat 5.8mg/15.8mg/20mg Capsule for pharmaceutical procurement in Washington, USA? This oral anticancer combination contains Gimeracil 5.8mg, Oteracil 15.8mg and Tegafur 20mg. Before comparing quotations, confirm the exact pack, manufacturer information, remaining shelf life and documents available for the offered batch.
Ernest Impex LLP is the business enquiry contact for importers, pharmaceutical distributors, wholesalers and healthcare procurement teams. Product availability and the suitability of the proposed supply route require confirmation before an order is accepted.
Understanding the Three Ingredients
The tegafur, gimeracil and oteracil combination is also known as S-1. Its components perform different roles:
| Ingredient | Stated amount per capsule | Role in the combination |
|---|---|---|
| Tegafur | 20mg | Converts in the body to fluorouracil, an anticancer medicine |
| Gimeracil | 5.8mg | Slows the breakdown of fluorouracil |
| Oteracil | 15.8mg | Reduces fluorouracil activity in normal gut tissue, helping limit gastrointestinal toxicity |
These roles are described in the European Medicines Agency’s information for Teysuno, a medicine containing the same combination. They explain the formulation; they do not establish approval or identical clinical performance for every brand. European Medicines Agency (EMA)
When preparing a purchase specification, keep each ingredient beside its strength. Some listings place Tegafur first, while your requested product name places Gimeracil first. Matching the ingredient–strength pairs helps prevent selection errors.
What Is the Product Used For?
This combination belongs to the oral chemotherapy category. Under its European authorisation, Teysuno is used with cisplatin for advanced gastric cancer and in defined circumstances for metastatic colorectal cancer. Tegonat’s permitted uses must be checked against its own approved prescribing information. European Medicines Agency (EMA)
It should be selected and monitored by an oncology specialist. A procurement listing cannot determine whether it is appropriate for an individual patient.
Buyers reviewing oncology medicines should distinguish the product’s labelled indication from broader uses discussed for its ingredients.
Key Benefits and Important Limits
The combination brings an anticancer ingredient and two supporting components into one oral capsule. Its therapeutic purpose is to help control cancer growth within an appropriate treatment regimen.
The oral presentation can form part of a specialist treatment plan, but it still requires monitoring. It should not be advertised as a guaranteed cure, a treatment for every cancer or a medicine without serious side effects.
Important risks described for the combination include reduced blood-cell counts and fatigue. DPD enzyme function and kidney function can affect treatment suitability and dosing. These assessments belong to the treating oncology team. European Medicines Agency (EMA)
Product Specifications for Buyers
| Specification | Information |
|---|---|
| Requested product name | Tegonat 5.8mg/15.8mg/20mg Capsule |
| Composition | Gimeracil 5.8mg + Oteracil 15.8mg + Tegafur 20mg |
| Dosage form | Oral capsule |
| Product category | Anticancer combination |
| Manufacturer supplied for this listing | Natco Pharma Ltd.; confirm on the offered pack |
| NATCO portfolio name | TEGONAT 20 |
| Business enquiry contact | Ernest Impex LLP |
| Labelled marketer | Confirm from the actual packaging |
| Pack quantity | Confirm before quotation approval |
| Shelf life and storage | Follow the current batch label |
| Target audience | Importers, distributors, wholesalers and healthcare procurement teams |
NATCO lists TEGONAT 20 in its oncology portfolio. Ernest Impex LLP is identified here as the procurement contact; its status as the labelled marketer or an authorised NATCO distributor has not been independently verified.
Quality Checks That Matter Before Purchase
For this product, correct strength identification is an essential first check. Compare the actual carton and blister labels with the quotation and purchase order.
Request readable packaging photographs, batch details, expiry dates and traceable source records. Ask which batch documents are available, including a certificate of analysis where obtainable.
Confirm that:
- All three ingredients and strengths match the requested formulation.
- Batch numbers and date markings are consistent.
- Packaging is intact, with no damaged or leaking capsules.
- The agreed minimum remaining shelf life will be met.
- Documents identify the relevant product, manufacturer and batch.
A photograph can help identify visible discrepancies, but it does not establish authenticity on its own. Review the records together and resolve mismatches before accepting stock.
Use pharmaceutical quality checks as an internal-link anchor if a matching page exists on your website.
Washington, USA Procurement Considerations
NATCO’s domestic oncology page includes an India-only sales notice. Confirm the applicable territorial restrictions for Tegonat before considering a U.S. transaction.
FDA also checks applicable drug approval, registration, listing, labelling and manufacturing requirements when medicines are offered for U.S. import. Approval of another brand or approval in another country does not establish U.S. eligibility for Tegonat.
This page therefore provides buyer information rather than confirmation of routine supply in Washington.
Clear Quotations and Handling Arrangements
A useful quotation should specify the exact presentation, capsules per pack, number of packs, price basis, remaining shelf life and available documents.
Follow the storage conditions printed on the actual product label. Agree on transport packaging and receiving arrangements, including the procedure for damaged goods or discrepancies. Receiving facilities should apply their procedures for handling cytotoxic medicines.
Link medicine storage and transport to a relevant existing guidance page where available.
Enquire Through Ernest Impex LLP
Send your organisation details, required quantity, preferred pack size, minimum shelf life and documentation requirements. Include the full destination address and specify Washington State or Washington, D.C.
Contact Ernest Impex LLP to request product information and assessment of the proposed transaction. Territorial permissions and U.S. eligibility should be resolved before any purchase or shipment commitment.
Frequently Asked Questions
1. What does Tegonat 5.8mg/15.8mg/20mg Capsule contain?
The requested composition is Gimeracil 5.8mg, Oteracil 15.8mg and Tegafur 20mg per capsule. Verify these ingredient–strength pairs on the actual pack.
2. Why does the capsule contain three ingredients?
Tegafur provides the anticancer component, Gimeracil slows fluorouracil breakdown, and Oteracil helps reduce its activity in normal gut tissue. European Medicines Agency (EMA)
3. Is this medicine suitable for every cancer patient?
No. Suitability depends on the diagnosis, authorised indication, treatment regimen and patient assessment. An oncology specialist must make that decision.
4. What should wholesalers verify before ordering?
Check the exact formulation, pack quantity, manufacturer, batch details, expiry, packaging condition and source documentation. Agree on minimum remaining shelf life in writing.
5. Does this listing confirm U.S. availability or FDA approval?
No. Neither has been established for this specific brand. Applicable territorial restrictions and U.S. transaction requirements must be verified first.
